1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi:10.3322/caac.21834 PMid:38572751
2. Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, et al. Global Disparities of Cancer and Its Projected Burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi:10.1001/jamanetworkopen.2024.43198 PMid:39499513 PMCid:PMC11539015
3. Robertson J, Barr R, Shulman LN, Forte GB, Magrini N. Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ. 2016;94(10):735-42. doi:10.2471/BLT.15.163998 PMid:27843163 PMCid:PMC5043203
4. Jenei K, Aziz Z, Booth C, Cappello B, Ceppi F, de Vries EGE, et al. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022; 10(12):e1860-e6. doi:10.1016/S2214-109X(22)00376-X PMid:36183737
5. Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer--the example of mechlorethamine. N Engl J Med. 2012;367(26):2461-3. doi:10.1056/NEJMp1212468 PMid:23268661
6. Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, et al. Impact of oncology drug shortages on patient therapy: unplanned treatment changes. J Oncol Pract. 2013;9(4):e122-8. doi:10.1200/JOP.2012.000799 PMid:23942928 PMCid:PMC3710178
7. Gatesman ML, Smith TJ. The Shortage of Essential Chemotherapy Drugs in the United States. N Engl J Med. 2011;365(18):1653-5. doi:10.1056/NEJMp1109772 PMid:22040130
8. Eid D, Jabbour J, Moujaes E, Kourie HR, Safieddine M, Kattan J. Impact of the economic crisis and drug shortage on Lebanese cancer patients' care. World J Clin Oncol. 2024;15(5):644-52. doi:10.5306/wjco.v15.i5.644 PMid:38835845 PMCid:PMC11145953
9. McBride A, Hudson-DiSalle S, Pilz J, Hamm M, Boring B, Buie LW, et al. National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association Survey. JCO Oncol Pract. 2022;18(8):e1289-e96. doi:10.1200/OP.21.00883 PMid:35544740
10. Malta M, Christian M, Cadwallader AB. Oncology Drug Shortages: Impacts, Policy Reforms, and Advocacy Imperatives. Cancer J. 2025;31(5). doi:10.1097/PPO.0000000000000784 PMid:41002877 PMCid:PMC12459138
11. Jenei K, Lythgoe MP, Vokinger KN. Shortages of essential cancer medicines: who is responsible and what are the possible solutions? Lancet Oncol. 2024;25(1):23-6. doi:10.1016/S1470-2045(23)00470-9 PMid:38181805
12. Santos ES, Oliver TK, Lacchetti C, Geisel R, Wilfong LS, Fader AN, et al. Drug Shortages in Oncology: ASCO Clinical Guidance for Alternative Treatments. JCO Oncol Pract. 2023;20(1):19-32. doi:10.1200/OP.23.00545 PMid:37963306
13. Goldsack JC, Reilly C, Bush C, McElligott S, Bristol MN, Motanya UN, et al. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014;71(7):571-8. doi:10.2146/ajhp130569 PMid:24644117
14. Ventola CL. The drug shortage crisis in the United States: causes, impact, and management strategies. P T. 2011;36(11):740-57.
15. Caulder CR, Mehta B, Bookstaver PB, Sims LD, Stevenson B. Impact of Drug Shortages on Health System Pharmacies in the Southeastern United States. Hosp Pharm. 2015;50(4):279-86. doi:10.1310/hpj5004-279 PMid:26448658 PMCid:PMC4589883
16. Reich L, Knopf KB. The Oncology Drug Shortages and Its Impact on Community Hospitals. Cancer J. 2025;31(5). doi:10.1097/PPO.0000000000000794 PMid:41002879
17. Cherny NI, Sullivan R, Torode J, Saar M, Eniu A. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Ann Oncol. 2017;28(11):2633-47. doi:10.1093/annonc/mdx521 PMid:28950323 PMCid:PMC5834140
18. Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. Clin Pharmacol Ther. 2013; 93(2):170-6. doi:10.1038/clpt.2012.220 PMid:23337525
19. McLaughlin M, Kotis D, Thomson K, Harrison M, Fennessy G, Postelnick M, et al. Empty shelves, full of frustration: consequences of drug shortages and the need for action. Hosp Pharm. 2013; 48 (8): 617-8. doi:10.1310/hpj4808-617 PMid:24421528 PMCid:PMC3847976
20. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Committee on Security of America's Medical Product Supply Chain. In: Shore C, Brown L, Hopp WJ, editors. Building Resilience into the Nation's Medical Product Supply Chains. Washington (DC): National Academies Press (US); 2022.
21. Socal MP, Acha J, Yang CY, Sun Y, Dada M, Dai T, et al. Key Drivers and Mitigation Strategies of Oncology Drug Shortages 2023 to 2025. Cancer J. 2025;31(5). doi:10.1097/PPO.0000000000000791 PMid:41002876 PMCid:PMC12459136
22. Hantel A, Spence R, Camacho P, Bradbury AR, Denburg AE, Jagsi R, et al. ASCO Ethical Guidance for the Practical Management of Oncology Drug Shortages. J Clin Oncol. 2024;42(3):358-65. doi:10.1200/JCO.23.01941 PMid:38061010
23. Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, et al. Drug Shortage: Causes, Impact, and Mitigation Strategies. Front Pharmacol. 2021;12:693426. doi:10.3389/fphar.2021.693426 PMid:34305603 PMCid:PMC8299364
24. Franco C. A simulation model to evaluate pharmaceutical supply chain costs in hospitals: the case of a Colombian hospital. Daru. 2020;28(1):1-12. doi:10.1007/s40199-018-0218-0 PMid:30565158 PMCid:PMC7214596
25. Pall R, Gauthier Y, Auer S, Mowaswes W. Predicting drug shortages using pharmacy data and machine learning. Health Care Manag Sci. 2023;26(3):395-411. doi:10.1007/s10729-022-09627-y PMid:36913071 PMCid:PMC10009839
26. Nabayiga H, Meer RVD, Agha MSA. A systematic review of simulation models in medicine supply chain management: Current state and emerging trends. Decis Anal J. 2025;14:100555. doi:10.1016/j.dajour.2025.100555
27. Tucker EL, Daskin MS. Pharmaceutical supply chain reliability and effects on drug shortages. Comput Ind Eng. 2022;169:108258. doi:10.1016/j.cie.2022.108258
28. Aronson JK, Heneghan C, Ferner RE. Drug shortages. Part 2: Trends, causes and solutions. Br J Clin Pharmacol. 2023;89(10): 2957-63. doi:10.1111/bcp.15853 PMid:37455465
29. Donohue JM, Angus DC. National Shortages of Generic Sterile Injectable Drugs: Norepinephrine as a Case Study of Potential Harm. JAMA. 2017;317(14):1415-7. doi:10.1001/jama.2017.2826 PMid:28322412
30. Yu YB, Briggs KT, Taraban MB, Brinson RG, Marino JP. Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics. Pharm Res. 2021;38(1):3-7. doi:10.1007/s11095-021-03008-w PMid:33555493 PMCid:PMC7869771
31. Pauwels K, Simoens S, Casteels M, Huys I. Insights into European drug shortages: a survey of hospital pharmacists. PLoS One. 2015; 10 (3):e0119322. doi:10.1371/journal.pone.0119322 PMid:25775406 PMCid:PMC4361582
32. Fox ER, McLaughlin MM. ASHP guidelines on managing drug product shortages. Am J Health Syst Pharm. 2018;75(21):1742-50. doi:10.2146/ajhp180441 PMid:30061155
33. Aronson JK, Heneghan C, Ferner RE. Drug shortages. Part 1. Definitions and harms. Br J Clin Pharmacol. 2023;89(10):2950-6. doi:10.1111/bcp.15842 PMid:37455356
34. De Weerdt E, Simoens S, Casteels M, Huys I. Toward a European definition for a drug shortage: a qualitative study. Front Pharmacol. 2015;6:253. doi:10.3389/fphar.2015.00253 PMid:26578963 PMCid:PMC4626567
35. Fox ER, Sweet BV, Jensen V. Drug shortages: a complex health care crisis. Mayo Clin Proc. 2014;89(3):361-73. doi:10.1016/j.mayocp.2013.11.014 PMid:24582195
36. Aronson JK. When I use a word Drug stock-outs. BMJ. 2025; 389:r1088. doi:10.1136/bmj.r1088 PMid:40409788
37. Shukar S, Shahid MH, Zhang J, Din SM, Khan FU, Fang Y, et al. Pharmacists' approach to oncology medicine shortages: results of a cross-sectional survey in Pakistan. BMJ Open. 2023;13(9):e070634. doi:10.1136/bmjopen-2022-070634 PMid:37723107 PMCid:PMC10510916
38. Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, et al. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist. 2014;19(2):186-92. doi:10.1634/theoncologist.2013-0301 PMid:24449096 PMCid:PMC3926786
39. Cherif Chefchaouni A, Moutaouakkil Y, Adouani B, Tadlaoui Y, Lamsaouri J, Bousliman Y. Impact of anti-cancer drugs shortages in oncology and hematology departments in a Moroccan hospital. J Oncol Pharm Pract. 2022;28(4):822-6. doi:10.1177/10781552211008212 PMid:33840285
40. Westin J, Sherwood S, Hagerty K, Gralow J. Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions. JCO Oncol Pract. 2025;OP-25-00381. doi:10.1200/OP-25-00381 PMid:40591897
41. Pineda-Moncusí M, Rekkas A, Martínez Pérez Á, Leis A, Lopez Gomez C, Fey E, et al. Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study. Lancet Public Health. 2025;10(10):e835-e47. doi:10.1016/S2468-2667(25)00194-X PMid:40992879
42. Cornelissen N, Zielhuis SW, van den Bemt PMLA, van den Bemt BJF. Causes and management of drug shortages: a scoping review. Res Social Adm Pharm. 2025. doi:10.1016/j.sapharm.2025.10.008 PMid:41168038
43. Sabogal De La Pava ML, Tucker EL. Drug shortages in low- and middle-income countries: Colombia as a case study. J Pharm Policy Pract. 2022;15(1):42. doi:10.1186/s40545-022-00439-7 PMid:35698240 PMCid:PMC9189796
44. Barrios C, de Lima Lopes G, Yusof MM, Rubagumya F, Rutkowski P, Sengar M. Barriers in access to oncology drugs - a global crisis. Nat Rev Clin Oncol. 2023;20(1):7-15. doi:10.1038/s41571-022-00700-7 PMid:36380066 PMCid:PMC9665041
45. Kanan M, Alraya R, Aljabri A, Alsaadi B, Althubyani M, Alamri S, et al. Tackling Drug Shortages: An In-Depth Systematic Review Protocol. Pharm Pract (Granada). 2025;23(1):1-8. doi:10.18549/PharmPract.2025.2.3127
46. Alfaouri M, Jaaron AAM, Igudia E. Pharmaceutical Supply Chain Management Challenges in Developing Countries: A Systematic Literature Review. J Afr Bus. 2025;26(4):798-841. doi:10.1080/15228916.2025.2532943
47. Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021;22(10):1367-77. doi:10.1016/S1470-2045(21)00463-0 PMid:34560006
48. Unguru Y, Fernandez CV, Bernhardt B, Berg S, Pyke-Grimm K, Woodman C, et al. An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer. J Natl Cancer Inst. 2016;108(6):djv392. doi:10.1093/jnci/djv392 PMid:26825103
49. Liu H, Zou L, Song Y, Yan J. Cost analysis of implementing a vial-sharing strategy for chemotherapy drugs using intelligent dispensing robots in a tertiary Chinese hospital in Sichuan. Front Public Health. 2022;10:936686. doi:10.3389/fpubh.2022.936686 PMid:36211656 PMCid:PMC9534289
50. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Implications of Discarded Weight-Based Dosing. In: Nass SJ, Lustig TA, Amankwah FK, Shortliffe EH, editors. Medications in Single-Dose Vials: Implications of Discarded Drugs. Washington (DC): National Academies Press (US); 2021.
51. Burry LD, Barletta JF, Williamson D, Kanji S, Maves RC, Dichter J, et al. It Takes a Village Contending With Drug Shortages During Disasters. Chest. 2020;158(6):2414-24. doi:10.1016/j.chest.2020.08.015 PMid:32805237 PMCid:PMC7426714
52. Chen E, Goold S, Harrison S, Ali I, Makki I, Kent SS, et al. Drug shortage management: A qualitative assessment of a collaborative approach. PLoS One. 2021;16(4):e0243870. doi:10.1371/journal.pone.0243870 PMid:33891609 PMCid:PMC8064571
53. Nierengarten MB. Guidance for patient care during drug shortages: Current and ongoing drug shortages that include two of the most widely used chemotherapy agents for treating common cancers are compounding the stress for patients and oncologists. Cancer. 2023;129(19):2924-5. doi:10.1002/cncr.34992 PMid:37656152
54. Melidis C, Vantsos M. [Comment] Ethical and practical considerations on cancer recommendations during COVID‑19 pandemic. Mol Clin Oncol. 2020;13(3):5. doi:10.3892/mco.2020.2075 PMid:32754319 PMCid:PMC7391840
55. Ravela R, Airaksinen M, Lyles A. State of the European Union's early notification obligation for drug shortages: enforcement and compliance in eight European countries (2020-2022). J Pharm Policy Pract. 2023;16(1):135. doi:10.1186/s40545-023-00646-w PMid:37936250 PMCid:PMC10629130
56. DeBoer RJ, Fadelu TA, Shulman LN, Van Loon K. Applying Lessons Learned From Low-Resource Settings to Prioritize Cancer Care in a Pandemic. JAMA Oncol. 2020;6(9):1429-33. doi:10.1001/jamaoncol.2020.2976 PMid:32761149
57. George S, Elrashid S. Inventory Management and Pharmaceutical Supply Chain Performance of Hospital Pharmacies in Bahrain: A Structural Equation Modeling Approach. Sage Open. 2023;13(1): 21582440221149717. doi:10.1177/21582440221149717
58. U.S. Food and Drug Administration. 7 Things to Know About Drug Shortage Management [Internet]. Silver Spring (MD): FDA; 2024 [cited 2025]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/7-things-know-about-drug-shortage-management
59. Government of Canada. Drug shortages in Canada: Regulations and guidance. Ottawa: Health Canada; 2025.
60. European Medicines Agency. European Shortages Monitoring Platform fully operational for monitoring of shortages in the EU. Amsterdam: EMA; 2025.
61. Michigan Department of Health. Recommendations for Ethical Allocation of Carboplatin and Cisplatin. Lansing (MI): MDH; 2023.
62. Rajangom KS, Erenay FS, He Q-M, Figueiredo R, Chan KKW, Cheung MC, et al. Cancer Drug Wastage and Mitigation Methods: A Systematic Review. Value Health. 2025;28(1):148-60. doi:10.1016/j.jval.2024.08.006 PMid:39343092
63. Song I. Predictive Analytics on Drug Shortages and Future Challenges: A Review. HIRA. 2025;5(2):85-97. doi:10.52937/hira.25.5.2.e4
64. Wai DF, Merchant RF, Donneyong MM. Optimizing Medication Distribution in Automated Dispensing Cabinets: Dashboard Implementation and Evaluation. J Pharm Pract. 2023;36(6):1404-11. doi:10.1177/08971900221118159 PMid:35953085
65. Bednarski BP, Singh AD, Jones WM. On collaborative reinforcement learning to optimize the redistribution of critical medical supplies throughout the COVID-19 pandemic. J Am Med Inform Assoc. 2021;28(4):874-8. doi:10.1093/jamia/ocaa324 PMid:33295626 PMCid:PMC7799039
66. Shah A, Khan S, Arman M. Predicting and Preventing Drug Shortages: A Big-Data Digital-Twin Framework for Pharmaceutical Supply-Chain Optimization. J Econ Finance Account Stud. 2024;6:116-26. doi:10.32996/jefas.2024.6.6.9
67. Kulkarni Kale U, Vemulapalli G. Integrating AI into the Clinical Workflows Across the Cancer Care Continuum: Opportunities and Challenges. Cancer J. 2025;31(6). doi:10.1097/PPO.0000000000000799 PMid:41252130
68. Dienes B, Qorri D, Felföldi J. Pharma supply chain resilience. A systematic review. Appl Stud Agribus Commer. 2024;18. doi:10.19041/APSTRACT/2024/1/8
69. Ravangard R, Raeyat Mohtashami A, Bouzanjani A, Siadat N, Ahmadi Marzaleh M. Assessing the Resilience of the Supply Chain of Medicines and Consumables during Disasters Based on the World Economic Forum Framework: A Case of Iran. Disaster Med Public Health Prep. 2025;19:1-9. doi:10.1017/dmp.2025.10192 PMid:40968779
70. Takawira B, Pooe D, Samuels A. Assessing Disruptions In Pharmaceutical Supply Chains: A Qualitative Study Of Resilience And Risks In The South African Context. J Supply Chain Manag. 2024;11:43-62.
71. Vadaga AK, Dokuburra UR, Nekkanti H, Gudla SS, R KK. Digital transformation in pharmaceuticals: The impact of AI on supply chain management. Intell Hosp. 2025;1(1):100008. doi:10.1016/j.inhs.2025.100008
72. Roy A, Mohapatra A, Sharwan C, Kumar A, Kumar S, Maholay A, et al. Artificial Intelligence in pharmaceutical supply chain management: A systemic review. World J Biol Pharm Health Sci. 2025;21:204-13. doi:10.30574/wjbphs.2025.21.1.1088
73. Shen J, Bu F, Ye Z, Zhang M, Ma Q, Yan J, et al. Management of drug supply chain information based on "artificial intelligence + vendor managed inventory" in China: perspective based on a case study. Front Pharmacol. 2024;15:1373642. doi:10.3389/fphar.2024.1373642 PMid:39081951 PMCid:PMC11286579
74. Grossman GM, Helpman E, Lhuillier H. Supply Chain Resilience: Should Policy Promote International Diversification or Reshoring? J Polit Econ. 2023;131(12):3462-96. doi:10.1086/725173
75. Badejo O, Ierapetritou M. Enhancing pharmaceutical supply chain resilience: A multi-objective study with disruption management. Comput Chem Eng. 2024;188:108769. doi:10.1016/j.compchemeng.2024.108769
76. Hosseini Shekarabi SA, Kiani Mavi R, Romero Macau F. Supply Chain Resilience: A Critical Review of Risk Mitigation, Robust Optimisation, and Technological Solutions and Future Research Directions. Glob J Flex Syst Manag. 2025;26(3):681-735. doi:10.1007/s40171-025-00458-8
77. Li Y, Omain S, Tan K. Supply Chain Resilience: A Review and Research Direction. Int J Acad Res Bus Soc Sci. 2021;11. doi:10.6007/IJARBSS/v11-i12/11985
78. Hernandez I, Sullivan SD, Hansen RN, Fendrick AM. Cheaper is not always better: Drug shortages in the United States and a value-based solution to alleviate them. J Manag Care Spec Pharm. 2024;30 (7): 719-27. doi:10.18553/jmcp.2024.30.7.719 PMid:38950157 PMCid:PMC11217858
79. Guo Y, Liu F, Song J-S, Wang S. Supply chain resilience: A review from the inventory management perspective. Fundam Res. 2025;5(2):450-63. doi:10.1016/j.fmre.2024.08.002 PMid:40242541 PMCid:PMC11997565
80. Marmolejo-Saucedo JA. Design and Development of Digital Twins: a Case Study in Supply Chains. Mob Netw Appl. 2020;25(6):2141-60. doi:10.1007/s11036-020-01557-9 PMid:40476942 PMCid:PMC7275123
81. Al-Hourani S, Weraikat D. A Systematic Review of Artificial Intelligence (AI) and Machine Learning (ML) in Pharmaceutical Supply Chain (PSC) Resilience: Current Trends and Future Directions. Sustainability. 2025;17(14). doi:10.3390/su17146591
82. Nuta S, Mattam AS, Marri NR, Polenwar S. Artificial Intelligence in Pharmaceutical Supply Chain Management. IJSAT-Int J Sci Technol. 2025;16(3). doi:10.71097/IJSAT.v16.i3.7919
83. Jones J. AI-Driven Demand Forecasting in Supply Chains: A Qualitative Analysis of Adoption and Impact. Preprints. 2025. doi:10.20944/preprints202501.1349.v1
84. Meknassi Salime G, Bhirich N, Cherif Chefchaouni A, El Hamdaoui O, El Baraka S, Elalaoui Y. Assessment of Automation Models in Hospital Pharmacy: Systematic Review of Technologies, Practices, and Clinical Impacts. Hosp Pharm. 2025. doi:10.1177/00185787251315622 PMid:40026489 PMCid:PMC11869230
85. Joshi SV, Patil SB, Patil SN, Bhosle S, Karhadkar NP, Rathore YK. Machine Learning Applications in Hospital Pharmacy for Predicting Drug Shortages and Supply Chain Optimization. Res J Pharm Technol. 2025;18(6):2939-45. doi:10.52711/0974-360X.2025.00393
86. Kaur A, Prakash G. Intelligent inventory management: AI-driven solution for the pharmaceutical supply chain. Societal Impacts. 2025;5:100109. doi:10.1016/j.socimp.2025.100109
87. Santos JAM, Lopes MR, Viegas JL, Vieira SM, Sousa JMC. Internal Supply Chain Digital Twin of a Pharmaceutical Company. IFAC-PapersOnLine. 2020;53(2):10797-802. doi:10.1016/j.ifacol.2020.12.2864
88. Suri GS, Kaur G, Shinde D. Beyond boundaries: exploring the transformative power of AI in pharmaceuticals. Discov Artif Intell. 2024;4(1):82. doi:10.1007/s44163-024-00192-7
89. Roman E-A, Stere A-S, Roșca E, Radu A-V, Codroiu D, Anamaria I. State of the Art of Digital Twins in Improving Supply Chain Resilience. Logistics. 2025;9(1). doi:10.3390/logistics9010022
90. Hupman AC, Zhang J, Li H. Predicting pharmaceutical supply chain disruptions before and during the COVID-19 pandemic. Risk Anal. 2024;44(12):2797-811. doi:10.1111/risa.17453 PMid:39212118
91. Jaberidoost M, Olfat L, Hosseini A, Kebriaeezadeh A, Abdollahi M, Alaeddini M, et al. Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods. J Pharm Policy Pract. 2015;8(1):9. doi:10.1186/s40545-015-0029-3 PMid:25838919 PMCid:PMC4354976
92. Chen Y, Yang O, Sampat C, Bhalode P, Ramachandran R, Ierapetritou M. Digital Twins in Pharmaceutical and Biopharmaceutical Manufacturing: A Literature Review. Processes. 2020;8(9). doi:10.3390/pr8091088
93. Elkefi S, Asan O. Digital Twins for Managing Health Care Systems: Rapid Literature Review. J Med Internet Res. 2022;24(8):e37641. doi:10.2196/37641 PMid:35972776 PMCid:PMC9428772
94. Da Silva LC. Artificial Intelligence as an Extension of Pharmaceutical Care. J Hosp Pharm Health Serv. 2025;16(3):e1420. doi:10.30968/jhphs.2025.163.1420
95. Mousazadeh M, Torabi SA, Zahiri B. A robust possibilistic programming approach for pharmaceutical supply chain network design. Comput Chem Eng. 2015;82:115-28. doi:10.1016/j.compchemeng.2015.06.008
96. Goswami A, Baveja A, Ding X, Melamed B, Roberts F. An integrated framework for modeling pharmaceutical supply chains with disruptions and risk mitigation. Ann Oper Res. 2024. doi:10.1007/s10479-024-06381-y
97. Kungwalsong K, Cheng C-Y, Yuangyai C, Janjarassuk U. Two-Stage Stochastic Program for Supply Chain Network Design under Facility Disruptions. Sustainability. 2021;13(5). doi:10.3390/su13052596
98. Nikzad E, Bashiri M, Oliveira F. Two-stage stochastic programming approach for the medical drug inventory routing problem under uncertainty. Comput Ind Eng. 2019;128:358-70. doi:10.1016/j.cie.2018.12.055
99. Russell HV, Bernhardt MB, Berg S. Using decision modeling to guide drug allocation during a shortage. Pediatr Blood Cancer. 2017;64(7). doi:10.1002/pbc.26331 PMid:27862980
100. Hantel A, McManus ML, Wadleigh M, Cotugno M, Abel GA. Impact of Allocation on Survival During Intermittent Chemotherapy Shortages: A Modeling Analysis. J Natl Compr Canc Netw. 2022;20(4):335-41.e17. doi:10.6004/jnccn.2021.7047 PMid:35390765 PMCid:PMC10983800
101. Hantel A, Peppercorn J, Abel GA. Model solutions for ethical allocation during cancer medicine shortages. Lancet Haematol. 2021;8(4):e246-e8. doi:10.1016/S2352-3026(21)00055-7 PMid:33770477
102. Vicente JJ. Optimizing Supply Chain Inventory: A Mixed Integer Linear Programming Approach. Systems. 2025;13(1). doi:10.3390/systems13010033
103. Vázquez-Serrano JI, Peimbert-García RE, Cárdenas-Barrón LE. Discrete-Event Simulation Modeling in Healthcare: A Comprehensive Review. Int J Environ Res Public Health. 2021; 18 (22). doi:10.3390/ijerph182212262 PMid:34832016 PMCid:PMC8625660
104. Vecillas Martin D, Berruezo Fernández C, Gento Municio AM. Systematic Review of Discrete Event Simulation in Healthcare and Statistics Distributions. Appl Sci. 2025;15(4). doi:10.3390/app15041861
105. Gan Z, Fu Z, Dong P, Ju Y, Shen Y. Computational modeling and analysis of medical resource shortages in hospital alliance: A simulation-driven approach. PLoS One. 2025;20(8):e0330871. doi:10.1371/journal.pone.0330871 PMid:40857292 PMCid:PMC12380337
106. Bastani P, Sadeghkhani O, Ravangard R, Rezaei R, Bikine P, Mehralian G. Designing a resilience model for pharmaceutical supply chain during crises: a grounded theory approach. J Pharm Policy Pract. 2021;14(1):115. doi:10.1186/s40545-021-00399-4 PMid:34969402 PMCid:PMC8717826
107. Organisation for Economic Co-operation and Development. Securing Medical Supply Chains in a Post-Pandemic World. Paris: OECD Publishing; 2024.
108. Faiman B. Providing Care During Cancer Drug Shortages. J Adv Pract Oncol. 2023;14(5):356-7. doi:10.6004/jadpro.2023.14.5.1 PMid:37576367 PMCid:PMC10414530
109. Pathak N, Shrestha R, Shrestha S. Improving patient outcomes during cancer drug shortages: the role of patient education. Eur J Hosp Pharm. 2025;32(5):397-8. doi:10.1136/ejhpharm-2025-004548 PMid:40169182
110. Tisoskey SP, Ford DW, Locantore-Ford PA. Communicating the Crisis: Navigating the Challenges of Chemotherapeutic Drug Shortages with a Patient-Centered Ethical Dialogue Framework. Blood. 2023;142:5171. doi:10.1182/blood-2023-190243
111. Shickh S, Leventakos K, Lewis MA, Bombard Y, Montori VM. Shared Decision Making in the Care of Patients With Cancer. Am Soc Clin Oncol Educ Book. 2023;43:e389516. doi:10.1200/EDBK_389516 PMid:37339391
112. Toorajipour R, Sohrabpour V, Nazarpour A, Oghazi P, Fischl M. Artificial intelligence in supply chain management: A systematic literature review. J Bus Res. 2021;122:502-17. doi:10.1016/j.jbusres.2020.09.009
113. Abu-El-Ruz R, Hasan A, Hijazi D, Masoud O, Abdallah AM, Zughaier SM, et al. Artificial Intelligence in Biomedical Sciences: A Scoping Review. Br J Biomed Sci. 2025;82:14362. doi:10.3389/bjbs.2025.14362 PMid:40837680 PMCid:PMC12360964
114. Tucker EL, Cao Y, Fox ER, Sweet BV. The Drug Shortage Era: A Scoping Review of the Literature 2001-2019. Clin Pharmacol Ther. 2020;108(6):1150-5. doi:10.1002/cpt.1934 PMid:32521038
115. Elleuch H, Dafaoui E, Elmhamedi A, Chabchoub H. Resilience and Vulnerability in Supply Chain: Literature review. IFAC-PapersOnLine. 2016;49(12):1448-53. doi:10.1016/j.ifacol.2016.07.775
116. Katsoulakis E, Wang Q, Wu H, Shahriyari L, Fletcher R, Liu J, et al. Digital twins for health: a scoping review. NPJ Digit Med. 2024; 7 (1):77. doi:10.1038/s41746-024-01073-0 PMid:38519626 PMCid:PMC10960047
